Consistent with this, lower endogenous SHBG levels have been robustly associated with increased risk for cardiometabolic disorders and non-alcoholic fatty liver disease across both sexes and age groups (24, 71, 72). The gene discussed is SHBG; the disease is metabolic dysfunction-associated steatotic liver disease.